JP2025511403A - 癌を治療するための併用療法 - Google Patents

癌を治療するための併用療法 Download PDF

Info

Publication number
JP2025511403A
JP2025511403A JP2024559036A JP2024559036A JP2025511403A JP 2025511403 A JP2025511403 A JP 2025511403A JP 2024559036 A JP2024559036 A JP 2024559036A JP 2024559036 A JP2024559036 A JP 2024559036A JP 2025511403 A JP2025511403 A JP 2025511403A
Authority
JP
Japan
Prior art keywords
azd5305
prostate cancer
pharma
acceptable salt
abiraterone acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511403A5 (enExample
Inventor
キアーラ コスリッチ，サビーナ
エス ブラウン，ジェシカ
アール アルバーテラ，マーク
レオ，エリザベッタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2025511403A publication Critical patent/JP2025511403A/ja
Publication of JP2025511403A5 publication Critical patent/JP2025511403A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2024559036A 2022-04-07 2023-04-06 癌を治療するための併用療法 Pending JP2025511403A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362614P 2022-04-07 2022-04-07
US63/362,614 2022-04-07
PCT/EP2023/059123 WO2023194525A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (2)

Publication Number Publication Date
JP2025511403A true JP2025511403A (ja) 2025-04-15
JP2025511403A5 JP2025511403A5 (enExample) 2026-04-10

Family

ID=86184958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559036A Pending JP2025511403A (ja) 2022-04-07 2023-04-06 癌を治療するための併用療法

Country Status (11)

Country Link
US (1) US20250228847A1 (enExample)
EP (1) EP4504147A1 (enExample)
JP (1) JP2025511403A (enExample)
KR (1) KR20240170958A (enExample)
CN (1) CN118973555A (enExample)
AU (1) AU2023250030A1 (enExample)
CA (1) CA3254950A1 (enExample)
IL (1) IL316019A (enExample)
MX (1) MX2024012369A (enExample)
TW (1) TW202404592A (enExample)
WO (1) WO2023194525A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325384A1 (en) * 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regimen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
EA201992430A1 (ru) * 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
CN118973555A (zh) 2024-11-15
CA3254950A1 (en) 2023-10-12
KR20240170958A (ko) 2024-12-05
MX2024012369A (es) 2024-11-08
AU2023250030A1 (en) 2024-11-07
EP4504147A1 (en) 2025-02-12
US20250228847A1 (en) 2025-07-17
TW202404592A (zh) 2024-02-01
IL316019A (en) 2024-11-01
WO2023194525A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
AU2013205648B2 (en) Combination treatment
JP2021504384A (ja) Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ
JP2025511402A (ja) 癌を治療するための併用療法
JP2025511401A (ja) 癌を治療するための併用療法
US20250228847A1 (en) Combination therapy for treating cancer
CN115038447A (zh) 用于治疗癌症的组合疗法
CZ20022981A3 (cs) Hormonální léčba u karcinomu prsu
JP2026515235A (ja) 癌を治療するためのｐａｒｐ１阻害剤と選択的エストロゲン分解薬の併用
US20170196853A1 (en) Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
KR20260020107A (ko) 다발성 경화증을 치료하기 위한 btk 억제제
WO2023016551A1 (zh) 用于治疗或预防抗宿主病的吡咯并六元杂芳物
KR20260036532A (ko) 약학적 조성물 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260402